Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: Long-term results and efficacy of adjuvant chemotherapy

Radiotherapy and Oncology

Volumn 88, Issue 3, 2008, Pages 351-358

  Chen, Yongshun ^a   Guo, Wenhao ^b   Lu, You ^a,b   Zou, Bingwen ^a  

^a CHENGDU UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Hypofractionation; Lung cancer; Stereotactic radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; STEROID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGITIS; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTERSTITIAL PNEUMONIA; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STEREOTACTIC PROCEDURE; SURVIVAL RATE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WHOLE BODY RADIATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; STEREOTAXIC TECHNIQUES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 52049102626     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.07.013     Document Type: Article

References (42)

1. Parkin D.M. Global cancer statistics in the year of 2000. Lancet Oncol 2 (2001) 533-543
2. Jemal A., Murray T., Ward E., et al. Cancer statistics 2006. CA Cancer J Clin 56 (2006) 106-130
3. Pirozynski M. 100 Years of lung cancer. Respir Med 12 (2006) 2073-2084
4. Zorn G.L., and Nesbitt J.C. Surgical management of early stage lung cancer. Semin Surg Oncol 18 (2000) 124-136
5. Senan S., and Lagerwaard F.J. The role of radiotherapy in non-small cell lung cancer. Ann Oncol 16 (2005) 223-228
6. Jassem J. The role of radiotherapy in lung cancer: where is the evidence?. Radiother Oncol 83 (2007) 203-213
7. Nyman J., Johansson K.A., and Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer 51 (2006) 97-103
8. Rowell N.P., and Williams C.J. Radical radiotherapy for stage I/II non small cell lung cancer in patents not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 56 (2001) 28-638
9. Verellen D., Soete G., Linthout N., et al. Optimal control of set-up margins and internal margins for intra- and extracranial radiotherapy using stereoscopic kilovoltage imaging. Cancer Radiother 10 (2006) 235-244
10. Bunn J.P. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer 6 (2004) 85-98
11. Bral S., Parijs H.V., Soete G., et al. A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized non-small cell lung cancer. Radiother Oncol 84 (2007) 252-256
12. Nagata Y., Takayama K., Matsuo Y., et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 53 (2005) 1427-1431
13. Hof H., Herfarth K., Münter M., et al. Stereotactic single-dose radiotherapy of stage I NSCLC. Int J Radiat Oncol Biol Phys 56 (2003) 335-341
14. Whyte R., Crownover R., Murphy M., et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg 75 (2003) 1097-1101
15. Rosell R., Delena M., Carpagnano F., et al. Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients. Lung Cancer 49 (2005) S3-S4
16. Winton T., Livingstone R., Johnson D., et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR. J Clin Oncol 22 (2004) 7018
17. Strauss G., Herndon J., and Maddaus M. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of cancer and leukaemia group B (CALGB) Protocol 9633. J Clin Oncol 22 (2004) 7019
18. Xia T.Y., Li H.Q., Sun Q.X., et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 66 (2006) 117-125
19. Chen M., James A.H., Randall K.T., et al. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys 64 (2006) 120-126
20. Hoopers D.J., Tann M., Fletcher J.W., et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 56 (2007) 229-234
21. Onishi H., Araki T., Shirato H., et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101 (2004) 1623-1631
22. Nagata Y., Negoro Y., Aoki T., et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 52 (2002) 1041-1046
23. Senan S., Ruysscher D., Giraud P., et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71 (2004) 139-146
24. Jeremic B. Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in nonsmall cell lung cancer (NSCLC). Enough to convert noelective into elective nodal irradiation (ENI)?. Radiother Oncol 71 (2004) 123-125
25. Chang D.T., Zlotecki R.A., and Olivier K.R. Re-examining the role of elective nodal irradiation: finding ways to maximize the therapeutic ratio. Am J Clin Oncol 28 (2005) 597-602
26. Doddoli C., Aragon A., Barlesi F., et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small cell lung cancer?. Eur J Cardiothorac Surg 27 (2005) 680-685
27. Lardinois D., Suter H., Hakki H., et al. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg 80 (2005) 268-274
28. Suzuki K., Nagai K., Yoshida J., et al. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg 117 (1999) 593-598
29. Withers H.R., and Suwinski R. Radiation dose response for subclinical metastases. Semin Radiat Oncol 8 (1998) 224-228
30. Delaney G., Barton M., Jacob S., et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 4 (2003) 120-128
31. Kong F.M., Randall K.T., Matthew J.S., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2 (2005) 324-333
32. Saunders M, Dische S, Barret A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicenter trial. CHART Steering Committee.
33. Claude L., Pérol D., Ginestet C., et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 71 (2004) 175-181
34. Holloway C.L., Robinson D., Murray B., et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 73 (2004) 285-287
35. Gajra A., Newman N., Gamble G.P., et al. Impact of tumor size on survival in stage IA nonsmall cell lung cancer: a case for subdividing stage IA disease. Lung Cancer 42 (2003) 51-57
36. Birim O., Kappetein A.P., Takkenberg J.J., et al. Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters. Ann Thorac Surg 79 (2005) 1137-1141
37. Tsuchiya T., Akamine S., Muraoka M., et al. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 56 (2007) 341-348
38. Hoffman P.C., Mauer A.M., and Vokes E.E. Lung cancer. Lancet 355 (2000) 479-485
39. Tiseo M., Franciosi V., Grossi F., et al. Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?. Eur J Cancer 42 (2006) 8-16
40. Arriagada R., Bergman B., Dunant A., et al. Cisplatin- based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350 (2004) 351-360
41. Hotta K., Matsuo K., Ueoka H., et al. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22 (2004) 3860-3867
42. Anne M.F., Sophie B., Anthony G., et al. Lung cancer in elderly patients: a retrospective analysis of practice in a single institution. Critic Rev Oncol Hematol 64 (2007) 43-48